Imaging test for prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial studies a new imaging agent called RAX301, which may help doctors see prostate cancer more clearly during a PET/CT scan. It is being tested in two groups of men: those scheduled for prostate removal surgery and those with a rising PSA after previous treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Men aged 18 or older
- Diagnosed with prostate cancer
- For the surgery group: scheduled to have radical prostatectomy (removal of the prostate) and pelvic lymph node dissection
- For the surgery group: prostate cancer is considered unfavorable intermediate, high-risk, or very high-risk
- For the recurrence group: rising PSA levels after radical prostatectomy or after radiation therapy
- Good kidney function (creatinine clearance at least 50 mL/min)
- Able to undergo PET/CT imaging
- No prior treatment with androgen deprivation therapy (ADT) or other neoadjuvant therapy for the surgery group
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new PET scan called XACP3 to see if it can find prostate cancer as well as the standard PSMA PET scan. You could help by having both scans to compare them.
This research study tests a new imaging scan (called 68Ga-OncoACP3-PET/CT) to help find prostate cancer and see where it may have spread. The scan uses a radioactive tracer to help doctors visualize cancer cells and decide on the best treatment options.
This trial tests a special type of scan (99mTc-MIP-1404 SPECT/CT) to see how well it can detect the spread of high-risk prostate cancer. It may help doctors better understand the stage of the disease before deciding on treatment.
This study uses a special scan called PET/MR with a prostate-focused tracer to help doctors choose the best next treatment for prostate cancer. It may be most helpful if you are planning major treatment or if your cancer has come back after prior treatment.
This trial compares a new imaging agent (61Cu-NU101) against the current standard imaging scan (Pylarify) to see which one better detects prostate cancer that has spread to a few sites in the body. Both use PET/CT scans, which are advanced imaging tools that help doctors locate cancer.
This trial tests a new imaging agent called INR101 to improve PET/CT scans for prostate cancer. It is for men with intermediate-risk or higher localized prostate cancer who are planning to have their prostate removed along with nearby lymph nodes. The goal is to see how well INR101 helps doctors see cancer during imaging.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.